Show simple item record

dc.contributor.authorMyers-Franchi, Bronwyn
dc.contributor.authorBouton, T.C.
dc.contributor.authorRagan, E.J.
dc.contributor.authorWhite, L.F.
dc.contributor.authorMcIlleron, H.
dc.contributor.authorTheron, D.
dc.contributor.authorParry, C.D.H.
dc.contributor.authorHorsburgh, C.R.
dc.contributor.authorWarren, R.M.
dc.contributor.authorJacobson, K.R.
dc.date.accessioned2021-09-24T06:57:29Z
dc.date.available2021-09-24T06:57:29Z
dc.date.issued2018
dc.identifier.citationMyers, B. and Bouton, T.C. and Ragan, E.J. and White, L.F. and McIlleron, H. and Theron, D. and Parry, C.D.H. et al. 2018. Impact of alcohol consumption on tuberculosis treatment outcomes: A prospective longitudinal cohort study protocol. BMC Infectious Diseases. 18 (1): Article No. 488.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/85650
dc.identifier.doi10.1186/s12879-018-3396-y
dc.description.abstract

Background: An estimated 10% of tuberculosis (TB) deaths are attributable to problematic alcohol use globally, however the causal pathways through which problem alcohol use has an impact on TB treatment outcome is not clear. This study aims to improve understanding of these mechanisms. Specifically, we aim to 1) assess whether poor TB treatment outcomes, measured as delayed time-to-culture conversion, are associated with problem alcohol use after controlling for non-adherence to TB pharmacotherapy; and 2) to determine whether pharmacokinetic (PK) changes in those with problem alcohol use are associated with delayed culture conversion, higher treatment failure/relapse rates or with increased toxicity.

Methods: Our longitudinal, repeated measures, prospective cohort study aims to examine the associations between problem alcohol use and TB treatment outcomes and to evaluate the effect of alcohol on the PK and pharmacodynamics (PD) of TB drugs. We will recruit 438 microbiologically confirmed, pulmonary TB patients with evidence of rifampicin susceptibility in Worcester, South Africa with 200 HIV uninfected patients co-enrolled in the PK aim. Participants are followed for the six months of TB treatment and an additional 12 months thereafter, with sputum collected weekly for the first 12 weeks of treatment, alcohol consumption measures repeated monthly in concert with an alcohol biomarker (phosphatidylethanol) measurement at baseline, and in person directly observed therapy (DOT) using real-time mobile phone-based adherence monitoring. The primary outcome is based on time to culture conversion with the second objective to compare PK of first line TB therapy in those with and without problem alcohol use.

Discussion: Globally, an urgent need exists to identify modifiable drivers of poor TB treatment outcomes. There is a critical need for more effective TB treatment strategies for patients with a history of problem alcohol use. However, it is not known whether poor treatment outcomes in alcohol using patients are solely attributable to noncompliance. This study will attempt to answer this question and provide guidance for future TB intervention trials. Trial registration: Clinicaltrials.gov Registration Number: NCT02840877. Registered on 19 July 2016.

dc.languageEnglish
dc.publisherBMC
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectInfectious Diseases
dc.subjectTuberculosis
dc.subjectMycobacterium tuberculosis
dc.subjectAlcohol
dc.subjectPharmacokinetics
dc.subjectTreatment adherence
dc.subjectTreatment outcome
dc.subjectMULTIDRUG-RESISTANT TUBERCULOSIS
dc.subjectWESTERN CAPE PROVINCE
dc.subjectINTESTINAL-ABSORPTION
dc.subjectCIPROFLOXACIN ANALOGS
dc.subjectIN-SITU
dc.subjectPHARMACOKINETICS
dc.subjectHIV
dc.subjectACETYLATION
dc.subjectIMMUNITY
dc.subjectETHANOL
dc.titleImpact of alcohol consumption on tuberculosis treatment outcomes: A prospective longitudinal cohort study protocol
dc.typeJournal Article
dcterms.source.volume18
dcterms.source.number1
dcterms.source.issn1471-2334
dcterms.source.titleBMC Infectious Diseases
dc.date.updated2021-09-24T06:57:26Z
curtin.note

© The Author(s). 2018 Published in BMC Infectious Diseases. This article is published under the Open Access publishing model and distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/. Please refer to the licence to obtain terms for any further reuse or distribution of this work.

curtin.departmentEnAble Institute
curtin.accessStatusOpen access
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidMyers-Franchi, Bronwyn [0000-0003-0235-6716]
curtin.identifier.article-numberARTN 488
dcterms.source.eissn1471-2334
curtin.contributor.scopusauthoridMyers-Franchi, Bronwyn [7202684194]


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/